Related references
Note: Only part of the references are listed.Cannabidiol for Mood Disorders: A Call for More Research
Francesco Bartoli et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2021)
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
Jerome Sarris et al.
BMC PSYCHIATRY (2020)
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
Edward Chesney et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Towards Better Delivery of Cannabidiol (CBD)
Sophie Anne Millar et al.
PHARMACEUTICALS (2020)
Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis
Guy Hindley et al.
LANCET PSYCHIATRY (2020)
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
Tom P. Freeman et al.
LANCET PSYCHIATRY (2020)
Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis
David Fraguas et al.
SCHIZOPHRENIA BULLETIN (2019)
Measuring Disturbance of the Endocannabinoid System in Psychosis A Systematic Review and Meta-analysis
Amedeo Minichino et al.
JAMA PSYCHIATRY (2019)
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
Albert Batalla et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Cannabis use disorders among adults in the United States during a time of increasing use of cannabis
Wilson M. Compton et al.
DRUG AND ALCOHOL DEPENDENCE (2019)
Antipsychotic treatment failure in patients with psychosis and co-morbid cannabis use: A systematic review
Sam Reid et al.
PSYCHIATRY RESEARCH (2019)
Cannabidiol as a potential treatment for psychosis
Cathy Davies et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2019)
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
Marta Di Forti et al.
LANCET PSYCHIATRY (2019)
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis
Nicola Black et al.
LANCET PSYCHIATRY (2019)
SANRA-a scale for the quality assessment of narrative review articles
Christopher Baethge et al.
RESEARCH INTEGRITY AND PEER REVIEW (2019)
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
Philip McGuire et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Douglas L. Boggs et al.
PSYCHOPHARMACOLOGY (2018)
Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function
Celia J. A. Morgan et al.
TRANSLATIONAL PSYCHIATRY (2018)
Poverty matters: Cannabis use among people with serious mental illness: Findings from the United States survey on drug use and health, 2015
Giuseppe Carra et al.
INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY (2018)
Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use
Hannah Myles et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2016)
Marijuana Legalization: Impact on Physicians and Public Health
Samuel T. Wilkinson et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Therapeutic Potential of Cannabinoids in Psychosis
F. Markus Leweke et al.
BIOLOGICAL PSYCHIATRY (2016)
Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe
Giuseppe Carra et al.
PSYCHIATRY RESEARCH (2016)
Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis
Robin M. Murray et al.
WORLD PSYCHIATRY (2016)
Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study
Tabea Schoeler et al.
LANCET PSYCHIATRY (2016)
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
R. B. Laprairie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Correlates of dependence and treatment for substance use among people with comorbid severe mental and substance use disorders Findings from the Psychiatric and Addictive Dual Disorder in Italy (PADDI) Study
Giuseppe Carra et al.
COMPREHENSIVE PSYCHIATRY (2015)
Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol
Felipe V. Gomes et al.
SCHIZOPHRENIA RESEARCH (2015)
A systematic review of the antipsychotic properties of cannabidiol in humans
Tabitha A. Iseger et al.
SCHIZOPHRENIA RESEARCH (2015)
Immune system: A possible nexus between cannabinoids and psychosis
Paula Suarez-Pinilla et al.
BRAIN BEHAVIOR AND IMMUNITY (2014)
Neuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals: a Systematic Review
A. Batalla et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Amir Englund et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
Induction of Psychosis by Δ9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing
Sagnik Bhattacharyya et al.
ARCHIVES OF GENERAL PSYCHIATRY (2012)
Treatment of Cannabis Use Among People with Psychotic Disorders: A Critical Review of Randomised Controlled Trials
Amanda L. Baker et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. M. Leweke et al.
TRANSLATIONAL PSYCHIATRY (2012)
Cannabis, a complex plant: different compounds and different effects on individuals
Zerrin Atakan
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2012)
Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
Sagnik Bhattacharyya et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
Jaime E. C. Hallak et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2010)
Rate of Cannabis Use Disorders in Clinical Samples of Patients With Schizophrenia: A Meta-analysis
Johanna Koskinen et al.
SCHIZOPHRENIA BULLETIN (2010)
Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - A systematic review
Carsten Hjorthoj et al.
ADDICTIVE BEHAVIORS (2009)
High-potency cannabis and the risk of psychosis
Marta Di Forti et al.
BRITISH JOURNAL OF PSYCHIATRY (2009)
Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients:: Impact of cannabis use
F. Markus Leweke et al.
SCHIZOPHRENIA RESEARCH (2007)
Cannabidiol monotherapy for treatment-resistant schizophrenia
Antonio Waldo Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
Share Paper
